Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00661_DB01149_nanopub.RAGysaaau2RXS2FIDwigOOdQobSEC5bsdhDLgIAvkHbKU#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00661_DB01149 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00661_DB01149 label "DDI between Verapamil and Nefazodone - Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nefazodone is initiated, discontinued or dose changed. [drugbank_resource:DB00661_DB01149]" assertion.
- drugbank_resource:DB00661_DB01149 identifier "drugbank_resource:DB00661_DB01149" assertion.
- drugbank_resource:DB00661_DB01149 title "DDI between Verapamil and Nefazodone - Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Nefazodone is initiated, discontinued or dose changed." assertion.
- drugbank:DB01149 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01149 assertion.
- drugbank:DB00661 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00661_DB01149 assertion.